William M. Rosencrans

William M. Rosencrans

Auto-generated profile, based on publicly available information

William M. Rosencrans

Section on Molecular Transport, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Cell Calcium
Verified
Journal Article
Closed access
WRWilliam M. Rosencrans
William M. Rosencrans
MRMegha Rajendran
Megha Rajendran
SBSergey M. Bezrukov
Sergey M. Bezrukov
Tatiana RostovtsevaTatiana Rostovtseva
Tatiana Rostovtseva

1 May 2021 in Cell Calcium
Verified
Journal Article
Closed access
WRWilliam M. Rosencrans
William M. Rosencrans
VAVicente Aguilella
Vicente Aguilella
Tatiana RostovtsevaTatiana Rostovtseva
Tatiana Rostovtseva
SBSergey M. Bezrukov
Sergey M. Bezrukov

23 November 2019 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
ARamandine rovini
amandine rovini
PGPhilip A. Gurnev
Philip A. Gurnev
ABAlexandra Beilina
Alexandra Beilina
MQMaría Queralt-Martín
María Queralt-Martín
WRWilliam Rosencrans
William Rosencrans
Tatiana RostovtsevaTatiana Rostovtseva
Tatiana Rostovtseva

29 August 2025 in Science Advances
Verified
Journal Article
Open access
WRWilliam M. Rosencrans
William M. Rosencrans
RLRyan W. Lee
Ryan W. Lee
LMLogan McGraw
Logan McGraw
IHIan Horsburgh
Ian Horsburgh
TWTing-Yu Wang
Ting-Yu Wang
TCTsui-Fen Chou
Tsui-Fen Chou
The PINK1/Parkin pathway targets damaged mitochondria for degradation via mitophagy. Genetic evidence implicates impaired mitophagy in Parkinson’s disease, making its pharmacological enhancement a promising therapeutic strategy. Here, we characterize two mitophagy activators: a novel Parkin activator, FB231, and the reported PINK1 activator MTK458. Both compounds lower the threshold for mitochondrial toxins to induce PINK1/Parkin-mediated mitophagy. However, global proteomics revealed that FB231 and MTK458 independently induce mild mitochondrial stress, resulting in impaired mitochondrial function and activation of the integrated stress response, effects that result from PINK1/Parkin-independent off-target activities. We find that these compounds impair mitochondria by distinct mechanisms and synergistically decrease mitochondrial function and cell viability in combination with classical mitochondrial toxins. Our findings support a model whereby weak or “silent” mitochondrial toxins potentiate other mitochondrial stressors, enhancing PINK1/Parkin-mediated mitophagy. These insights highlight important considerations for therapeutic strategies targeting mitophagy activation in Parkinson’s disease.

19 June 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
MRMegha Rajendran
Megha Rajendran
MQMaría Queralt-Martín
María Queralt-Martín
PGPhilip A. Gurnev
Philip A. Gurnev
WRWilliam M. Rosencrans
William M. Rosencrans
ARamandine rovini
amandine rovini
Tatiana RostovtsevaTatiana Rostovtseva
Tatiana Rostovtseva
Involvement of alpha-synuclein (αSyn) in Parkinson’s disease (PD) is complicated and difficult to trace on cellular and molecular levels. Recently, we established that αSyn can regulate mitochondrial function by voltage-activated complexation with the voltage-dependent anion channel (VDAC) on the mitochondrial outer membrane. When complexed with αSyn, the VDAC pore is partially blocked, reducing the transport of ATP/ADP and other metabolites. Further, αSyn can translocate into the mitochondria through VDAC, where it interferes with mitochondrial respiration. Recruitment of αSyn to the VDAC-containing lipid membrane appears to be a crucial prerequisite for both the blockage and translocation processes. Here we report an inhibitory effect of HK2p, a small membrane-binding peptide from the mitochondria-targeting N-terminus of hexokinase 2, on αSyn membrane binding, and hence on αSyn complex formation with VDAC and translocation through it. In electrophysiology experiments, the addition of HK2p at micromolar concentrations to the same side of the membrane as αSyn results in a dramatic reduction of the frequency of blockage events in a concentration-dependent manner, reporting on complexation inhibition. Using two complementary methods of measuring protein-membrane binding, bilayer overtone analysis and fluorescence correlation spectroscopy, we found that HK2p induces detachment of αSyn from lipid membranes. Experiments with HeLa cells using proximity ligation assay confirmed that HK2p impedes αSyn entry into mitochondria. Our results demonstrate that it is possible to regulate αSyn–VDAC complexation by a rationally designed peptide, thus suggesting new avenues in the search for peptide therapeutics to alleviate αSyn mitochondrial toxicity in PD and other synucleinopathies.

1 October 2019 in Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
Verified
Journal Article
Closed access
WCWayland W.L. Cheng
Wayland W.L. Cheng
MBMelissa M. Budelier
Melissa M. Budelier
YSYusuke Sugasawa
Yusuke Sugasawa
LBLucie Bergdoll
Lucie Bergdoll
MQMaría Queralt-Martín
María Queralt-Martín
AEAlex S Evers
Alex S Evers